Abstract
Background Inflammation contributes to morbidity following subarachnoid hemorrhage (SAH). Transauricular vagus nerve stimulation (taVNS) offers a noninvasive approach to target the inflammatory response following SAH.
Methods In this prospective, triple-blinded, randomized, controlled trial, twenty-seven patients were randomized to taVNS or sham stimulation. Blood and cerebrospinal fluid (CSF) were collected to quantify inflammatory markers. Cerebral vasospasm severity and functional outcomes (modified Rankin Scale, mRS) were analyzed.
Results No adverse events occurred. Radiographic vasospasm was significantly reduced (p = 0.018), with serial vessel caliber measurements demonstrating a more rapid return to normal than sham (p < 0.001). In the taVNS group, TNF-α was significantly reduced in both plasma (days 7 and 10) and CSF (day 13); IL-6 was also significantly reduced in plasma (day 4) and CSF (day 13) (p < 0.05). Patients receiving taVNS had higher rates of favorable outcomes at discharge (38.4% vs 21.4%) and first follow-up (76.9% vs 57.1%), with significant improvement from admission to first follow-up (p = 0.014), unlike the sham group (p = 0.18). The taVNS group had a significantly lower rate of discharge to skilled nursing facility or hospice (p = 0.04).
Conclusion taVNS is a non-invasive method of neuro- and systemic immunomodulation. This trial supports that taVNS following SAH can mitigate the inflammatory response, reduce radiographic vasospasm, and potentially improve functional and neurological outcomes.
Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04557618
Competing Interest Statement
G.T, D.R, G.W.J, M.A, A.T.C, T.T.K, J.W.O, A.K.V, G.J.Z, and P.B. have no disclosures. A.L.H?s disclosures are as follows: Stock ownership: Aurenar, E.C.L?s disclosures are as follows: Stock ownership: Aurenar, Neurolutions, General Sensing, Osteovantage, Pear Therapeutics, Face to Face Biometrics, Caeli Vascular, Acera, Sora Neuroscience, Inner Cosmos, Kinetrix, NeuroDev. Consultant: Monteris Medical, E15, Acera, Alcyone, Intellectual Ventures, Neurolutions, Pear Therapeutics, Inc., Sante Ventures, SAB. Licensing from Intellectual Property: Neurolutions, Caeli Vascular. Licensing/Product Washington University owns equity in Neurolutions.
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT04557618
Clinical Protocols
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984059/
Funding Statement
Just in Time Funding, Washington University (ECL) AANS Robert J Dempsey, MD Cerebrovascular Research Award (ALH) The Aneurysm and AVM Foundation (ALH) National Institute of Neurological Disorders and Stroke, StrokeNet Fellowship Program (ALH) National Institute of Neurological Disorders and Stroke, R21-NS128307 (ECL, GJZ, PB) National Institute of Biomedical Imaging and Bioengineering, P41-EB018783 (ECL, PB) McDonnel Center for System Neuroscience (ECL, PB)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Washington University in St. Louis Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Non-Standard Abbreviations and Acronyms: CSD: cortical spreading depolarizations, CSF: cerebrospinal fluid, EVD: external ventricular drain, SAH: subarachnoid hemorrhage, taVNS: transauricular vagus nerve stimulation, TENS: transcutaneous electrical nerve stimulation, VNS: vagus nerve stimulation, taVNS: transauricular vagus nerve stimulation
Data Availability
All data is available upon reasonable request
